Eli Lilly made a big move by beating rival Novo Nordisk to launch its popular diabetic and weight-loss medication, Mounjaro (tirzepatide), in India on Thursday, March 20. India is the most populated country in the world and is facing an increase in obesity and diabetes rates.
The introduction coincides with a surge in investor interest in next-generation GLP-1 receptor agonists, which have revolutionized treatment choices and raised the market values of both pharmaceutical behemoths.
India offers a vital market for these treatments due to its fast increasing prevalence of metabolic disorders. Given the high cost of these medications in Western countries, industry experts predict that accessibility and affordability would be major issues in India. Nonetheless, Eli Lilly’s action shows a sustained dedication to growing its presence in developing nations.